Logo image of U.CA

Uranium Participation CO (U.CA) Stock Fundamental Analysis

Canada - TSX:U -

13.98
+0.01 (+0.07%)
Last: 2/18/2022, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, U scores 2 out of 10 in our fundamental rating. U was compared to 81 industry peers in the Capital Markets industry. U scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. U does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year U has reported negative net income.
U.CA Yearly Net Income VS EBIT VS OCF VS FCFU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 100M -100M -200M

1.2 Ratios

Industry RankSector Rank
ROA -21.32%
ROE 6.48%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
U.CA Yearly ROA, ROE, ROICU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 20 -20 -40

1.3 Margins

Industry RankSector Rank
OM 105.34%
PM (TTM) 106.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
U.CA Yearly Profit, Operating, Gross MarginsU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 20 40 60 80 100

More info and screens

5

2. Health

2.1 Basic Checks

U has less shares outstanding than it did 1 year ago.
U has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
U.CA Yearly Shares OutstandingU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
U.CA Yearly Total Debt VS Total AssetsU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

There is no outstanding debt for U. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
U.CA Yearly LT Debt VS Equity VS FCFU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

2.3 Liquidity

U has a Current Ratio of 4.95. This indicates that U is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.95
Quick Ratio N/A

More info and screens

3

3. Growth

3.1 Past

The earnings per share for U have decreased strongly by -166.47% in the last year.
U shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -51.28% yearly.
U shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -160.16%.
U shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.49% yearly.
EPS 1Y (TTM)-166.47%
EPS 3Y-51.28%
EPS 5YN/A
EPS Q2Q%-85.62%
Revenue 1Y (TTM)-160.16%
Revenue growth 3Y-48%
Revenue growth 5Y22.49%
Sales Q2Q%-84.39%

3.2 Future

U is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -29.23% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-52.84%
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%
EPS Next 5Y-29.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
U.CA Yearly Revenue VS EstimatesU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 0 100M -100M -200M
U.CA Yearly EPS VS EstimatesU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 -0.5 1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

U reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 49.84, which means the current valuation is very expensive for U.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.55, U is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 49.84
U.CA Price Earnings VS Forward Price EarningsU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -153.59
U.CA Per share dataU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A cheap valuation may be justified as U's earnings are expected to decrease with -37.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%

More info and screens

0

5. Dividend

5.1 Amount

U does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Uranium Participation CO

TSX:U (2/18/2022, 7:00:00 PM)

13.98

+0.01 (+0.07%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners32.17%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.10B
Revenue(TTM)-147381000
Net Income(TTM)-156671000
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 49.84
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.87
P/tB N/A
EV/EBITDA -153.59
EPS(TTM)-1.15
EYN/A
EPS(NY)0.28
Fwd EY2.01%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS-0.98
BVpS4.87
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.32%
ROE 6.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 105.34%
PM (TTM) 106.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y1%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover-0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.95
Quick Ratio N/A
Altman-Z N/A
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.47%
EPS 3Y-51.28%
EPS 5YN/A
EPS Q2Q%-85.62%
EPS Next Y-52.84%
EPS Next 2Y-39.98%
EPS Next 3Y-37.09%
EPS Next 5Y-29.23%
Revenue 1Y (TTM)-160.16%
Revenue growth 3Y-48%
Revenue growth 5Y22.49%
Sales Q2Q%-84.39%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Uranium Participation CO / U.CA FAQ

What is the fundamental rating for U stock?

ChartMill assigns a fundamental rating of 3 / 10 to U.CA.


What is the valuation status of Uranium Participation CO (U.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to Uranium Participation CO (U.CA). This can be considered as Overvalued.


How profitable is Uranium Participation CO (U.CA) stock?

Uranium Participation CO (U.CA) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for U stock?

The Earnings per Share (EPS) of Uranium Participation CO (U.CA) is expected to decline by -52.84% in the next year.